Once More Unto The Breach: 2014 NME Candidates Crowd In Familiar Fields
This article was originally published in Pharmaceutical Approvals Monthly
With new drug candidates concentrated in already crowded markets like diabetes, antithrombotics and oncology, in 2014 sponsors must be prepared to demonstrate value not just to regulators but to payers as well. Merck, Lilly and AstraZeneca account for one-third of pending novel agents as the companies seek to recover from the patent cliff.
You may also be interested in...
Bullish analysts predicted Xtandi easily wins over first-to-market Zytiga in pre-chemo prostate cancer, based on PREVAIL findings. But in the formal presentation at the ASCO GU meeting, clinicians were more reluctant to compare the two drugs and took a more nuanced interpretation of the data, given the important differences in study designs.
FDA’s top new drug official called out industry’s innovation model, noting that major primary care markets are being left underserved as sponsors focus on precision medicine and rare diseases.
Acquisition is based on the prospects for Immunomedics’ Trodelvy, but regulatory changes, manufacturing challenges, and research dynamics could upset even the best-laid plans.